Intracavitary chemotherapy (Gliadel®) for recurrent esthesioneuroblastoma: Case report and review of the literature

Michael C. Park, Charles E. Weaver, John E. Donahue, Prakash Sampath

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Esthesioneuroblastoma is an uncommon malignancy of the nasal vault with a treatment regimen consisting of surgical resection followed by radiotherapy for primary lesions and addition of chemotherapy for patients with advanced, recurrent or metastatic lesions. We report a case of a 39-year-old female with a history of esthesioneuroblastoma, previously treated with resection, radiation and chemotherapy, presenting with a recurrent disease that was successfully treated with re-resection and placement of Gliadel® wafers in the surgical resection cavity. The novel option of controlled-release and local delivery of a chemotherapeutic agent for treatment of recurrent esthesioneuroblastoma should be recognized and considered.

Original languageEnglish (US)
Pages (from-to)47-51
Number of pages5
JournalJournal of Neuro-Oncology
Volume77
Issue number1
DOIs
StatePublished - Mar 1 2006

Keywords

  • Carmustine
  • Controlled-release biodegradable polymer
  • Esthesioneuroblastoma
  • Gliadel®
  • Intracavitary chemotherapy
  • Local recurrence

Fingerprint Dive into the research topics of 'Intracavitary chemotherapy (Gliadel®) for recurrent esthesioneuroblastoma: Case report and review of the literature'. Together they form a unique fingerprint.

  • Cite this